• Featured Product
  • KD/KO Validated

PD-L1/CD274 (C-terminal) Polyclonal antibody

PD-L1/CD274 (C-terminal) Polyclonal Antibody for IF, IHC, IP, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human, mouse, rat and More (1)

Applications

WB, IP, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 28076-1-AP

Synonyms

B7 H, B7 H1, B7 homolog 1, B7H1, CD274, CD274 molecule, PD L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, PD-L1, PD-L1/CD274 (C-terminal), Programmed death ligand 1



Tested Applications

Positive WB detected inIFN gamma treated A549 cells, mouse heart tissue, rat heart tissue, MDA-MB-231 cells, human placenta tissue, THP-1 cells
Positive IP detected inhuman placenta tissue
Positive IHC detected inhuman tonsillitis tissue, human lung cancer tissue, human breast cancer tissue, human cervical cancer tissue, human placenta tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inhuman tonsillitis tissue

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:300-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB
Immunohistochemistry (IHC)IHC : 1:400-1:1600
Immunofluorescence (IF)IF : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

28076-1-AP targets PD-L1/CD274 (C-terminal) in WB, IP, IHC, IF, ELISA applications and shows reactivity with Human, mouse, rat samples.

Tested Reactivity Human, mouse, rat
Cited Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen PD-L1/CD274 (C-terminal) fusion protein Ag27557
Full Name CD274 molecule
Calculated molecular weight 290 aa, 33 kDa
Observed molecular weight 45-50 kDa
GenBank accession numberBC074984
Gene symbol CD274
Gene ID (NCBI) 29126
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1's implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).


Protocols

Product Specific Protocols
WB protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
IHC protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
IF protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
IP protocol for PD-L1/CD274 (C-terminal) antibody 28076-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Cancer Res

Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer.

Authors - Dalong Cao
IHC

Clin Cancer Res

PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.

Authors - Henry G Smith
humanWB,IF

Cancer Immunol Immunother

PMID: 30406373

Authors - Wenli Yuan
humanIHC

Front Oncol

Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.

Authors - Qiong Wang
humanWB

J Oral Pathol Med

All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.

Authors - Xiao-Jie Chen
humanWB

Biosci Rep

PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.

Authors - Hongmin Gao
  • KD Validated